Mnemo Therapeutics locks in Series A

Mnemo Therapeutics, a provider of epigenetic antigens, stronger T cells, has raised 75 million euros in Series A funding.

Mnemo Therapeutics, a provider of epigenetic antigens, stronger T cells, has raised 75 million euros in Series A funding. Casdin Capital led the round with participation from other investors that included Sofinnova Partners, Redmile, Emerson Collective and Alexandria Venture Investments.

Source: Press Release